within Pharmacolibrary.Drugs.ATC.N;

model N02BG08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0023333333333333335,
    adminDuration  = 600,
    adminMass      = 0.0012,
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ziconotide is a synthetic peptide derived from the venom of the marine cone snail Conus magus. It is a selective blocker of N-type voltage-gated calcium channels and is used for the management of severe chronic pain in patients who require intrathecal therapy and for whom other treatments have proven inadequate. Ziconotide is approved by the FDA for intrathecal administration in refractory chronic pain.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with severe chronic pain receiving intrathecal ziconotide.</p><h4>References</h4><ol><li>Jinping Lin, Shuwei Chen, Usman Dawood Butt, Min Yan, Bin Wu,A comprehensive review on ziconotide.,Heliyon,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38779019/'>https://pubmed.ncbi.nlm.nih.gov/38779019/</a></li><li>Gladstone C McDowell, Jason E Pope,Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.,Neuromodulation : journal of the International Neuromodulation Society,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26856969/'>https://pubmed.ncbi.nlm.nih.gov/26856969/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02BG08;
